vs

Side-by-side financial comparison of DBV Technologies S.A. (DBVT) and NORTH EUROPEAN OIL ROYALTY TRUST (NRT). Click either name above to swap in a different company.

DBV Technologies S.A. is the larger business by last-quarter revenue ($2.8M vs $2.2M, roughly 1.2× NORTH EUROPEAN OIL ROYALTY TRUST). NORTH EUROPEAN OIL ROYALTY TRUST runs the higher net margin — 87.2% vs -1195.5%, a 1282.7% gap on every dollar of revenue. On growth, NORTH EUROPEAN OIL ROYALTY TRUST posted the faster year-over-year revenue change (329.5% vs 158.8%).

DBV Technologies SA is a publicly owned French biopharmaceutical firm headquartered in Bagneux, France. DBV Technologies is known for developing "Viaskin" technology for administering allergens or antigens to intact skin while avoiding any transfer to the blood. Viaskin Peanut clinical development has received Fast Track designation from the US Food and Drug Administration.

North European Oil Royalty Trust is a publicly traded royalty trust holding overriding royalty interests in North Sea oil and gas producing properties. It earns revenue from its assets' production sales, distributing nearly all net income to unitholders regularly, with no active drilling or exploration operations.

DBVT vs NRT — Head-to-Head

Bigger by revenue
DBVT
DBVT
1.2× larger
DBVT
$2.8M
$2.2M
NRT
Growing faster (revenue YoY)
NRT
NRT
+170.7% gap
NRT
329.5%
158.8%
DBVT
Higher net margin
NRT
NRT
1282.7% more per $
NRT
87.2%
-1195.5%
DBVT

Income Statement — Q3 FY2025 vs Q1 FY2026

Metric
DBVT
DBVT
NRT
NRT
Revenue
$2.8M
$2.2M
Net Profit
$-33.2M
$1.9M
Gross Margin
Operating Margin
-1235.7%
Net Margin
-1195.5%
87.2%
Revenue YoY
158.8%
329.5%
Net Profit YoY
-8.9%
581.3%
EPS (diluted)
$-0.24

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DBVT
DBVT
NRT
NRT
Q1 26
$2.2M
Q3 25
$2.8M
Q2 25
$1.5M
Q1 25
$519.4K
Q2 24
$1.2M
Q1 24
$1.4M
Q4 23
$8.9M
Q3 23
$2.4M
Net Profit
DBVT
DBVT
NRT
NRT
Q1 26
$1.9M
Q3 25
$-33.2M
Q2 25
$-41.9M
Q1 25
$285.5K
Q2 24
$-33.1M
Q1 24
$-27.3M
Q4 23
$134.3M
Q3 23
$-16.7M
Operating Margin
DBVT
DBVT
NRT
NRT
Q1 26
Q3 25
-1235.7%
Q2 25
-2806.2%
Q1 25
Q2 24
-2914.9%
Q1 24
-2029.7%
Q4 23
-134.3%
Q3 23
-770.2%
Net Margin
DBVT
DBVT
NRT
NRT
Q1 26
87.2%
Q3 25
-1195.5%
Q2 25
-2858.4%
Q1 25
55.0%
Q2 24
-2852.4%
Q1 24
-1943.5%
Q4 23
1512.8%
Q3 23
-705.6%
EPS (diluted)
DBVT
DBVT
NRT
NRT
Q1 26
Q3 25
$-0.24
Q2 25
$-0.31
Q1 25
Q2 24
$-0.34
Q1 24
$-0.28
Q4 23
$-0.11
Q3 23
$-0.17

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DBVT
DBVT
NRT
NRT
Cash + ST InvestmentsLiquidity on hand
$69.8M
$3.9M
Total DebtLower is stronger
Stockholders' EquityBook value
$52.9M
Total Assets
$110.5M
$3.9M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DBVT
DBVT
NRT
NRT
Q1 26
$3.9M
Q3 25
$69.8M
Q2 25
$103.2M
Q1 25
Q2 24
$66.2M
Q1 24
$101.5M
Q4 23
$141.4M
Q3 23
$149.1M
Stockholders' Equity
DBVT
DBVT
NRT
NRT
Q1 26
Q3 25
$52.9M
Q2 25
$86.2M
Q1 25
Q2 24
$79.1M
Q1 24
$111.7M
Q4 23
$140.2M
Q3 23
$144.0M
Total Assets
DBVT
DBVT
NRT
NRT
Q1 26
$3.9M
Q3 25
$110.5M
Q2 25
$143.4M
Q1 25
Q2 24
$114.2M
Q1 24
$145.9M
Q4 23
$183.0M
Q3 23
$189.8M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DBVT
DBVT
NRT
NRT
Operating Cash FlowLast quarter
$-32.4M
Free Cash FlowOCF − Capex
$-32.6M
FCF MarginFCF / Revenue
-1173.5%
Capex IntensityCapex / Revenue
4.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-138.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DBVT
DBVT
NRT
NRT
Q1 26
Q3 25
$-32.4M
Q2 25
$-33.9M
Q1 25
Q2 24
$-35.1M
Q1 24
$-34.7M
Q4 23
$-13.7M
Q3 23
$-19.6M
Free Cash Flow
DBVT
DBVT
NRT
NRT
Q1 26
Q3 25
$-32.6M
Q2 25
$-33.9M
Q1 25
Q2 24
$-35.8M
Q1 24
$-36.0M
Q4 23
$-14.0M
Q3 23
$-19.6M
FCF Margin
DBVT
DBVT
NRT
NRT
Q1 26
Q3 25
-1173.5%
Q2 25
-2316.5%
Q1 25
Q2 24
-3084.0%
Q1 24
-2560.6%
Q4 23
-158.2%
Q3 23
-827.3%
Capex Intensity
DBVT
DBVT
NRT
NRT
Q1 26
Q3 25
4.2%
Q2 25
2.2%
Q1 25
Q2 24
63.0%
Q1 24
94.9%
Q4 23
4.0%
Q3 23
2.1%
Cash Conversion
DBVT
DBVT
NRT
NRT
Q1 26
Q3 25
Q2 25
Q1 25
Q2 24
Q1 24
Q4 23
-0.10×
Q3 23

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons